Loading
2 standard-of-care settings across 2 lines and 2 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| Triple-negative | Stage II to III | As for triple-negative disease; the subtype's lower pathological complete response rate is a research observation. | 98 |
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Metastatic, androgen receptor-positive (trials only) | Bicalutamide or enzalutamide showed clinical benefit rates of 19 to 33 percent in phase 2; not approved for breast cancer, so within a trial or after the approved options. | 91 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.